Prostate Cancer and the Mevalonate Pathway
Patricia Guerrero‐Ochoa, Sergio Rodríguez-Zapater, Alberto Anel, Luis Esteban, Alejandro Camón-Fernández, R. Espílez, María Jesús Gil‐Sanz, Ángel Borque‐Fernando
Abstract
Antineoplastic therapies for prostate cancer (PCa) have traditionally centered around the androgen receptor (AR) pathway, which has demonstrated a significant role in oncogenesis. Nevertheless, it is becoming progressively apparent that therapeutic strategies must diversify their focus due to the emergence of resistance mechanisms that the tumor employs when subjected to monomolecular treatments. This review illustrates how the dysregulation of the lipid metabolic pathway constitutes a survival strategy adopted by tumors to evade eradication efforts. Integrating this aspect into oncological management could prove valuable in combating PCa.